Compare TRMB & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRMB | NBIX |
|---|---|---|
| Founded | 1978 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 13.2B |
| IPO Year | 1996 | 1996 |
| Metric | TRMB | NBIX |
|---|---|---|
| Price | $54.19 | $163.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | $93.50 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 0.42 | ★ 1.91 |
| Revenue | ★ $3,798,700,000.00 | $161,626,000.00 |
| Revenue This Year | $9.92 | $24.73 |
| Revenue Next Year | $8.04 | $13.14 |
| P/E Ratio | $132.77 | ★ $87.58 |
| Revenue Growth | 3.33 | ★ 977.51 |
| 52 Week Low | $52.80 | $122.14 |
| 52 Week High | $87.50 | $169.57 |
| Indicator | TRMB | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 65.15 |
| Support Level | $52.80 | $134.92 |
| Resistance Level | $69.89 | N/A |
| Average True Range (ATR) | 1.89 | 4.51 |
| MACD | 0.24 | 0.13 |
| Stochastic Oscillator | 20.73 | 67.18 |
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.